Oppenheimer Asset Management Inc. Sells 6,723 Shares of Zoetis Inc. (NYSE:ZTS)

Oppenheimer Asset Management Inc. lessened its position in Zoetis Inc. (NYSE:ZTS) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 232,409 shares of the company’s stock after selling 6,723 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Zoetis were worth $37,866,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services purchased a new position in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis during the third quarter valued at approximately $33,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

ZTS has been the subject of several research reports. Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. StockNews.com lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Piper Sandler cut their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $215.40.

Zoetis Stock Performance

ZTS opened at $164.99 on Thursday. The firm has a market cap of $73.88 billion, a P/E ratio of 30.16, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a 50 day simple moving average of $166.22 and a two-hundred day simple moving average of $177.58. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is 36.56%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.